INCOME TAXES (Details) - USD ($) $ in Millions |
3 Months Ended | 6 Months Ended | |||
|---|---|---|---|---|---|
Aug. 02, 2026 |
Aug. 03, 2025 |
May 04, 2025 |
Aug. 02, 2026 |
Aug. 03, 2025 |
|
| Income Taxes [Abstract] | |||||
| Effective income tax rate | 49.20% | (101.60%) | 84.20% | 175.30% | |
| Income tax (benefit) | $ (99.7) | $ (113.0) | $ (79.2) | $ (417.8) | |
| (Loss) Income before taxes | (202.6) | 111.2 | (94.1) | (238.4) | |
| Goodwill and other intangible asset impairments | $ 439.0 | $ 0.0 | $ 479.5 | $ 439.0 | $ 479.5 |
| Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent | 26.90% | (122.90%) | 63.00% | 156.40% | |
| X | ||||||||||
- Definition Income Taxes [Abstract] No definition available.
|
| X | ||||||||||
- Definition Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of impairment loss for finite- and indefinite-lived intangible assets, goodwill, and capitalized cost for software to be sold, leased, or marketed. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|